Cantabio Pharmaceuticals Inc. (OTCMKTS:CTBO) Loses More Ground
tags: CTBO
Cantabio Pharmaceuticals Inc. (OTCMKTS:CTBO)’s latest fall began last Thursday, carried all the way through Friday’s trading session – but will it continue in this week?
Today’s early trading seems to indicate that it may yet manage to rally. Enterprising and aggressive investors may want to take that into account, as they eye CTBO for a window of opportunity for profitable trading.
However, said investors should only do so with the knowledge that paid pumps are the only reason the ticker has still not fallen back tot he illiquid obscurity which it had inhabited about a month ago. First it was OTCtipReporter and Wall Street Report, then when said notorious pumpers dropped the ticker, SmallCapLeader picked where they left off.
Their continued efforts managed to push the company’s market cap as far as $200 million – which is simply ludicrous, considering the fact that we’re talking about a company, whose latest financial report looked like this:
- Cash & total assets – $100 thousand
- Total Current Liabilities – $188 thousand
- Quarterly Net loss – $65 thousand
With this in mind, there is very little room for wonder at the fact that CTBO fell as hard as it did. After all, that’s what classic OTC Markets pump-jobs do in the end, and to date, there is no evidence that CTBO is anything but that.
What does that mean for the chances of the company retaining its current $60 million market cap in the long run? Investors should think long and hard on that question, as its answer may end up being important.
